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Chronic myeloid leukaemia (CML) arises after transformation of a haemopoietic stem cell 
(HSC) by the protein-tyrosine kinase BCR–ABL1. Direct inhibition of BCR–ABL1 kinase 
has revolutionized disease management, but fails to eradicate leukaemic stem cells (LSCs), 
which maintain CML. LSCs are independent of BCR–ABL1 for survival, providing a 
rationale for identifying and targeting kinase-independent pathways. Here we show—using 
proteomics, transcriptomics and network analyses—that in human LSCs, aberrantly 
expressed proteins, in both imatinib-responder and non-responder patients, are modulated 
in concert with p53 (also known as TP53) and c-MYC regulation. Perturbation of both p53 
and c-MYC, and not BCR–ABL1 itself, leads to synergistic cell kill differentiation, and 
near elimination of transplantable human LSCs in mice, while sparing normal HSCs. This 
unbiased systems approach targeting connected nodes exemplifies a novel precision 
medicine strategy providing evidence that LSCs can be eradicated. 
BCR-ABL1 is a chimaeric oncogene arising from the t(9;22)(q34;q11) chromosomal 
translocation. The resultant protein tyrosine kinase (PTK) drives signalling events
1
 and 
transforms HSCs. BCR–ABL1 activity in HSCs causes CML, which if untreated, is fatal. 
  
TK inhibitors (TKIs), such as imatinib mesylate, are standard CML treatment and have 
improved survival, justifying the use of single-target therapies
2
. However, these drugs do not kill 
the LSCs that maintain the disease
3
, resulting in ever-increasing costs to sustain remissions. TKI 
discontinuation in the best 10–20% of TKI responders led to relapse rates of 50–60%, 
reinforcing the need to understand and target CML LSCs
4
 with curative therapies. Recent studies 
suggest that LSC survival is BCR–ABL1-kinase independent5 and BCR–ABL1 has functionality 
beyond PTK activity, explaining the shortcomings of TKIs
6
. 
We have applied systems biology approaches to patient material to identify key protein 
networks that perpetuate the CML phenotype, aiming to elucidate potentially curative therapeutic 
options. Using unbiased transcriptomic and proteomic analyses, the transcription factors p53 and 
c-MYC are identified as having defining roles in CML LSC survival. We demonstrate an integral 
relationship between p53 and c-MYC in the maintenance of CML, and importantly, a potential 
therapeutic advantage they have as drug targets over BCR–ABL1 for eradication of CML LSCs. 
p53 and c-MYC mediate the CML network 
To interrogate perturbations in BCR–ABL1 signalling of potential therapeutic value, isobaric-tag 
mass spectrometry (MS) was used to compare treatment-naive CML and normal CD34
+
 cells. 
Fifty-eight proteins were consistently deregulated in three CML samples (Methods and 
Supplementary Table 1). Dijkstra’s algorithm7 and the MetaCore knowledge base 
(https://portal.genego.com/) were used to identify p53 and c-MYC as central hubs 
(Supplementary Table 2) in a CML network of 30 proteins (Fig. 1a) predominantly downstream 
of the transcription factors, with significant enrichment for p53/c-MYC targets (Fisher’s exact 
test, P = 0.001). While the majority of proteins downstream of p53 were downregulated, those 
downstream of c-MYC included proteins up- or downregulated in CML, in keeping with c-MYC 
acting as an activator and repressor of gene transcription
8
. The deregulated network suggests an 
altered dependency on p53 and c-MYC in CML CD34
+
 cells. 
This data set represents the first—to our knowledge—relative quantitative comparison of 
CML to normal CD34
+
 cells using MS. Importantly, CML-initiating cells reside within the 
CD34
+
CD38
−
Lin
−
 subpopulation and may differ to bulk CD34
+
 cells. To substantiate the CML 
proteome observations and investigate regulation in LSCs, we examined relevant, primary CML 
transcriptomic data. Network protein levels correlated well with respective gene levels, in both 
  
LSCs (four independent data sets; Fig. 1b and Extended Data Fig. 1a–c) and CD34+ progenitors 
(Extended Data Fig. 1d, e). Correlations were stronger for the 30 network candidates compared 
to all 58 deregulated proteins; seven data sets showed significant gain in r
2
 for network 
candidates (Extended Data Fig. 1a, d). The mutual information (MI) of proteomic/transcriptomic 
data for network proteins was significantly greater than random (Fig. 1c and Extended Data Fig. 
1b, e). This consistent messenger RNA/protein correspondence, in both progenitors and LSCs, 
confirmed that the network was transcriptionally regulated, compatible with c-MYC and p53 
function. 
p53 and c-MYC have key roles in oncogenesis and appear in many cancer networks. To 
distinguish true regulatory effectors, we assessed the bias towards outgoing versus incoming 
signalling (degreeout/degreein (dout/din)) or p53 and c-MYC. We generated networks from 
deregulated proteins in (1) primary MS data sets
9–11
, (2) cell lines transduced with oncogenic 
PTKs driving haematological malignancies
12
, and from (3) 50 randomly generated protein sets. 
Our network falls outside the expected random distribution and no other data set exhibits greater 
downstream bias for p53 and c-MYC (Fig. 1d). These data support a novel network in, and 
unique to, CML, centred on p53 and c-MYC. 
Validation of network candidates 
The CML network revealed well-characterized p53/c-MYC targets and proteins not previously 
associated with CML pathogenesis (Supplementary Table 3). To validate proteomic predictions 
(Fig. 1a), gelsolin, CIP2A (also known as KIAA1524), UCHL1, aldose reductase, p53 and c-
MYC were assessed using western blotting and immunofluorescence (Fig. 2a, b). Protein 
expression of gelsolin, CIP2A, UCHL1 and aldose reductase were consistent with CML network 
predictions (Fig. 2a). Immunofluorescence was confirmatory, highlighting the dramatic 
difference in CIP2A expression between normal and CML cells, and the intracellular localization 
of gelsolin and aldose reductase (Fig. 2b). CML cells also expressed increased c-MYC and 
decreased p53 levels (Fig. 2a, b), correlating well with appropriate modulation of downstream 
targets. We therefore hypothesized that simultaneous p53 activation and c-MYC inhibition 
would kill LSCs. To assess dual hub requirement for CML survival, lentiviral short hairpin RNA 
(shRNA) constructs (Extended Data Fig. 2a) were employed. Knockdown of HDM2 (also known 
as MDM2; E3 ligase/negative regulator for p53), c-MYC, or both, in CML CD34
+
 cells reduced 
  
viability and enhanced apoptosis; the combined effects were synergistic. In colony-forming cell 
(CFC) assays, effects were more dramatic with single or combined knockdown, strengthening 
the hypothesis that p53 and c-MYC are critical for the survival of CML cells (Fig. 2c–e and 
Extended Data Fig. 2b, c). We then investigated synergistic interactions between p53 and c-
MYC, testing clinically tractable inhibitors. 
RITA and CPI-203 synergize to drive CML CD34+ cell kill 
To target identified hubs, we selected RITA (also known as NSC 652287),which binds p53 and 
blocks its degradation, and CPI-203, a bromodomain and extra terminal protein (BET) inhibitor 
hindering transcription by disrupting chromatin-dependent signal transduction
13,14
. As 
anticipated
15
, c-MYC was downregulated 8 h after CPI-203 treatment (Extended Data Fig. 3a). 
CPI-203 also reduced p53 at 8 h. RITA subtly increased p53 by 8 h, further enhanced by 24–
48 h. Dasatinib (Das) at 150 nM (a concentration achievable in patients to fully inhibit BCR–
ABL
16
) gradually reduced p53 levels and inhibited phosphorylation of STAT5 as previously 
observed
17,18
. RITA with CPI-203 for 8 h reduced both p53 and c-MYC, suggesting a dominant 
effect of CPI-203 at this early time point, but by 48 h markedly increased p53 (Extended Data 
Fig. 3a–c). 
RITA or CPI-203 treatment of CML CD34
+
 cells for 72 h reduced viability in a 
concentration-dependent manner and induced significant apoptosis; combining drugs resulted in 
further significant reductions in these parameters (Fig. 3a, b and Extended Data Fig. 3d). 
Labelling with the cell division tracker carboxyfluorescein succinimidyl ester (CFSE) and CD34 
antibody showed that as CML cells divided in the presence of CPI-203, there was clear and rapid 
loss of CD34 expression not seen with RITA (Fig. 3c), suggesting that c-MYC (a predominant 
target of CPI-203; ref. 15) inhibition induces differentiation of CML CD34
+
 cells. Differentiation 
was further suggested by skewing of the morphology, size and number of CFCs (Fig. 3d). RITA 
decreased CFCs but did not affect colony types (Fig. 3d, e). By inducing apoptosis and 
differentiation, the drugs may synergize and enhance elimination of CML. By measuring drug–
dose response
19
, combination therapy was potently synergistic with combination indicies (CI) 
ranging from 0.07 to 0.34 (Fig. 3a). Nutlin-3a (Nut), another HDM2 inhibitor, produced similar 
results. The effects of RITA and Nut were p53 dependent, as K562 cells lacking p53 were non-
responsive (Extended Data Figs 3e and 4a, b). Since CPI-203 ± RITA reduced p53 at the early 
  
time point, sequential inhibition of HDM2 and c-MYC was tested using chemical and genetic 
approaches. Neither inhibition of HDM2 before c-MYC nor vice versa improved cell kill 
compared with simultaneous knockdown or drug inhibition, or compared with nilotinib (Nil) 
(Extended Data Fig. 4c, d). 
CML patients receive a TKI, irrespective of response. We therefore assessed RITA and 
CPI-203 effects in imatinib-mesylate-pre-treated CML CD34
+
 cells. Imatinib mesylate neither 
ameliorated nor enhanced the efficacy of RITA and/or CPI-203 (Extended Data Fig. 4e). 
RITA and CPI-203 eliminate LSCs 
The CML network suggested an altered dependency on p53/c-MYC signalling. We therefore 
hypothesized that normal cells may be less susceptible to the drug combination. Treatment of 
normal CD34
+
 cells with single agents or combinations had no significant effects on cell counts. 
However, increased apoptosis was observed at higher CPI-203 concentrations (2 or 5 M) and 
with the highest combination (RITA 25 nM, CPI-203 5 M; Extended Data Fig. 5a, b). In CML 
cells, apoptosis was observed with all four CPI-203 and combination concentrations (Fig. 3b), 
confirming a therapeutic window. 
To confirm the in silico results that led to the prediction (Fig. 1b, c and Extended Data 
Fig. 1c) that an altered dependency on p53 and c-MYC extended to primitive LSCs, we exposed 
CML LSCs to the drug combination. LSCs were defined as either CFSE
max
 or CD34
+
CD38
−
. As 
shown previously
16
, in comparison to untreated control, over 5 days the CFSE
max
 population 
persisted in response to Das and Nil, but was significantly reduced by CPI-203 alone and by 
combination treatment (Figs 3c and 4a, b). Over 72 h, RITA with CPI-203 was also effective in 
synergistically eliminating residual CD34
+
CD38
−
 cells (CI = 0.3–0.8; Extended Data Fig. 5c). 
HSCs and LSCs are most stringently defined by their engraftment capacity at 16 weeks. 
We exposed CML CD34
+
 cells to RITA, CPI-203, the combination, or Das for 48 h before 
transplantation into sublethally irradiated NSG mice (Extended Data Fig. 5d). Human CD45
+
 
cells were detectable in peripheral blood at 8, 12 and 16 weeks and in bone marrow at 16 weeks 
post-transplantation. Das had no significant effect on NSG-repopulating CML LSCs, 
representing the most primitive long-term engrafting cells. In contrast RITA, CPI-203, and the 
combination reduced engraftment as indicated by decreased CD45
+
, CD34
+
, CD33
+
, CD11b
+
, 
CD19
+
 and CD14
+
 cells (Extended Data Fig. 5e, f). Using a CML sample known to engraft both 
  
BCR–ABL1+ and BCR–ABL1− cells by double fusion fluorescence in situ hybridization (D-
FISH), there was a marked decrease in the long-term-engrafting potential of RITA-, CPI-203- or 
combination-treated leukaemic cells, with no significant effect on non-leukaemic populations 
(Fig. 4c, d and Extended Data Fig. 5g, h). Experiments using cord blood CD34
+
 cells confirmed 
the selectivity of RITA and CPI-203 for BCR–ABL1+ versus BCR–ABL1− stem cells (Fig. 4d). 
Mechanism of LSC kill and clinical scope 
To understand the mechanism(s) underlying reduction of CML stem and progenitor cells in 
response to RITA and CPI-203, RNA sequencing (RNA-seq) was performed. Of the 12,248 
genes sequenced, 2,134 were identified as synergistically modulated by combination treatment; 
166 demonstrated extreme synergy (Fig. 5a). Moreover, 81% of the genes differentially 
expressed in response to the combination were deregulated in the same direction with RITA or 
CPI-203 (2(1) = 891.93, P < 0.01). While transcriptional responses to RITA or CPI-203 were 
enriched for p53/apoptosis or c-MYC/differentiation (not found with Nil), respectively, the 
combination induced enhanced or additional enrichment of these molecular signatures and 
pathways (Fig. 5b, Extended Data Fig. 6a–c and Supplementary Tables 5–7). Furthermore, 
stem/progenitor markers CD34 and CD133 were dramatically downregulated by CPI-203 and the 
combination, but not by RITA or Nil (Extended Data Fig. 7b). The enrichment in the 
p53/apoptosis and c-MYC/differentiation pathways paralleled the in vitro phenotypic effects 
observed. Limited overlap in gene membership of the signatures identified in silico demonstrates 
that distinct molecular components contribute to single and combined drug responses (Fig. 5c). 
CML stem cell persistence is an issue for all CML patients, however, many also exhibit 
or acquire TKI resistance or demonstrate a more aggressive clinical phenotype
20
. These represent 
patients in whom novel agents targeting p53 and c-MYC would first be tested. To investigate 
whether the deregulated p53/c-MYC network is present in both TKI-responder (TKI-R) and 
TKI-non-responder (TKI-NR) patients
21
, and in more advanced forms of CML
20
, we considered 
data from CD34
+
 CML cells derived from suitable patient cohorts. Transcriptional expression of 
the network components was highly correlated across all CML versus normal comparisons, 
irrespective of TKI response or clinical phenotype (Fig. 5d). In keeping with these in silico data, 
CD34
+
 cells from a TKI-NR patient showed high levels of apoptosis after treatment with RITA 
  
and/or CPI-203 (Extended Data Fig. 7c), suggesting that these drugs should be of therapeutic 
value for such patients. 
RG7112/7388 and CPI-203/0610 therapy 
To progress the drug combination towards the clinic, we used complementary preclinical mouse 
models and introduced RG7112 and RG7388, both HDM2 inhibitors
22
, and CPI-0610, a BET 
inhibitor
23
; drugs already advanced in clinical trials in humans. In the SCL-tTA-BCR-ABL 
double transgenic (DTG) leukaemia mouse model BCR–ABL1, driven from the stem cell 
promoter (SCL), is inducible in HSCs by tetracycline withdrawal (tTA), resulting in a 
transplantable CML-like disease with increased myeloid counts and splenomegaly
16,17,24
. 
After irradiation, C57BL/6 CD45.1
+
 mice were used as recipients and CD45.2
+
 mice as 
DTG bone marrow donors (Extended Data Fig. 8a). After transplantation (to synchronize 
leukaemia development and assess transplantable LSCs), CML was induced. In mice and/or rats, 
RG7112 at 50–200 mg kg−1 and CPI-0610 at 15–60 mg kg−1 have demonstrated on-target effects 
in tumours
22,23
. Excellent tolerability was achieved with modest doses of RG7112 (50 mg kg
−1
 
once daily) and CPI-0610 (15 mg kg
−1
 twice daily, both for 4 weeks), selected to demonstrate 
synergy. White blood cell and neutrophil counts returned to non-leukaemic control levels with 
the drug combination, but not with single treatments (Fig. 6a and Extended Data Fig. 8b). While 
CPI-0610, Nil, and the combination significantly reduced spleen size (Fig. 6b), only the 
combination significantly reduced donor leukaemic CD45.2
+
 cells in the bone marrow (protected 
by the niche), while simultaneously allowing recovery of host normal CD45.1
+
 cells; 
CD45.1:CD45.2 ratio changed from 20:80 (untreated) to 40:60 (combination) (Extended Fig. 
Data 8c). At the stem cell level, donor leukaemic Lin
−
Sca-1
+
c-Kit
+
 (CD45.2
+
 LSK) cells were 
reduced by >60% by the combination, while host LSKs were unaffected. None of the single arms 
reduced LSKs (Fig. 6b–d), supporting the synergistic effects demonstrated in vitro. 
To confirm that these therapeutic in vivo effects extended to human CML, two cohorts of 
sublethally irradiated NSG mice were transplanted with independent CML CD34
+
 samples and 
treated with RG7388 and CPI-203 (75–100 mg kg−1 and 6–7.5 mg kg−1, respectively) for 3–4 
weeks. Of the single agents, only CPI-203 showed a consistent effect. The drug combination, 
however, eliminated 95% of Ph
+
CD45
+
 and 88% of CD45
+
CD34
+
 subsets (Fig. 6e, f). These 
results were significant as compared to vehicle (P < 0.001) or Nil (P = 0.0016 (CD45
+
); 
  
P = 0.0047 (CD45
+
CD34
+
)) and as compared to RG7388 (P = 0.0017 (CD45
+
); P = 0.0004 
(CD45
+
CD34
+
)) or CPI-203 (P = 0.0046 (CD45
+
); P = 0.0008 (CD45
+
CD34
+
)), respectively 
(Fig. 6e, f), again suggesting a high degree of synergy. 
Discussion 
This work demonstrates the potential of unbiased, systems approaches to uncover new 
therapeutic options by analysing primitive stem cell subsets from primary material. We found 
that p53 and c-MYC work together with BCR–ABL1 to shape leukaemia stem cell phenotype 
and show that modulation of both p53 and c-MYC is critical to drive synergistic enhancement of 
apoptosis and differentiation seen in vitro, in vivo, at the stem cell level and the molecular level 
by RNA-seq. 
p53 and c-MYC have individually been identified as proteins in CML pathobiology
17,25–30
 
and cancer
31–33
, but have not previously been considered for dual targeting. In recent CML 
studies, enhanced LSC kill converged on p53 as the mediator of apoptosis
17,25,34
. CML LSCs are 
also susceptible to enhancement or depletion of c-MYC. After deletion of the E3 ligase FBXW7, 
c-MYC increases with p53, resulting in cell cycle entry and p53-dependent apoptosis
29,30
. 
However, FBXW7 may not represent a viable drug target based on its role in haematopoiesis, 
tissue stem cells and, importantly, as a tumour suppressor. Currently, there is interest in drugging 
the spliceosome machinery, particularly for MYC-driven cancers, however, a therapeutic 
window remains to be established and exploited with well-tolerated agents
35,36
. BET inhibition is 
a rapidly expanding market with multiple agents in phase 1–2 development. These agents are 
well tolerated and demonstrate efficacy in haematological malignancies. Resistance to BET 
inhibitors evolves through epigenetic mechanisms
37
, however, our combination approach will be 
less susceptible to resistance. 
Over the last decade CML has been transformed from a fatal cancer to a manageable 
disease with lifelong therapy. Despite recognition that LSCs prevent cure, the paradigm 
established by TKIs means that novel drugs must be safe, supported by a clear therapeutic 
window and easy to administer. As a result, few preclinical studies have reached the clinic and 
trials fail owing to toxicity and poor recruitment
24,38
. CML is often regarded as a simple cancer, 
driven solely by BCR–ABL1, yet we do not understand why targeting BCR–ABL1 does not 
eradicate LSCs, nor cure CML. Our work shows that BCR–ABL1 reprograms potent 
  
oncoproteins and tumour suppressors, to establish a signalling network that underlies the 
propagation of CML. Critically, we found that simultaneous perturbation of p53 and c-MYC, 
mechanistically driving modulation of p53, apoptosis, c-MYC and differentiation pathways, 
improved selective kill of LSCs as compared to TKIs. Nil was ineffective against these 
pathways, potentially explaining why TKIs are not sufficient to cure CML. The fact that the 
aberrant network was similarly regulated in TKI-Rs, TKI-NRs, and patients with aggressive and 
indolent CML, coupled with the availability of well-tolerated oral agents in an advanced stage of 
development, now offers an entirely novel approach for the treatment of CML, with the 
therapeutic potential to address CML LSC persistence and improve outcome for CML patients. 
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Figure 1 p53 and c-MYC network in CML regulation. a, Network analysis reveals that c-
MYC and p53 are central in a putative CML network (n=3 patient samples, n=2 normal 
samples). b, Correlation between proteomic/transcriptomic deregulation in primitive 
CD34
+
Hst
lo
Py
lo
 (G0) (top two panels); CD34
+
CD38
−
 (second panel from the bottom) and 
Lin
−
CD34
+
CD38
−
CD90
+
 CML cells (bottom panel). Filled black circles indicate all 
  
protein/genes; filled red circles indicate network proteins/genes. rc, full candidate list correlation; 
rn, network correlation. c, Gene/protein MI for the CML network (red, false discovery rate 
(FDR) < 0.05; grey, FDR < 0.10); FDR calculated using 10,000 re-samplings (blue histogram). 
d, The dout/din ratio for p53 and c-MYC in haematological PTK-regulated cell lines (n=3 BaF/3 
technical replicates per transfected oncogene), other primary cancers and random protein 
networks. 
Figure 2 Validation of proteomic network. a, Network proteins, p53 and c-MYC western blots 
using CML and normal CD34
+
 cells. For gel source data, see Supplementary Fig. 1. b, Network 
proteins validated by immunofluorescence in CML and normal CD34
+
 cells labelled green or red 
(far left), with the nucleus stained blue using 4′,6-diamidino-2-phenylindole (DAPI; second left), 
overlays of images (second right), and three-dimensional fluorescent signal (far right). c, CML 
CD34
+
 cells after HDM2, c-MYC, or scramble knockdown (n = 6 patient samples). d, Apoptosis 
after knockdown (n = 4 patient samples). e, CFCs from knockdown (n = 3 patient samples). 
Values normalized to scrambled control, mean ± standard error of the mean (s.e.m.) (P values: 
two-tailed Student’s t-test; *P < 0.05, **P < 0.01, ***P < 0.001). 
Figure 3 Modulation of p53 and c-MYC demonstrates CML sensitivity. a, b, Drug titrations: 
cell viability with CIs (n = 3 patient samples) (a) and apoptosis (n = 3 patient samples) (b). c, 
CFSE/CD34-labelled cells. Cell divisions are multicoloured. Representative of n = 3 patient 
samples. d, CFCs from treated cells. Representative of n = 3 patient samples. e, Averaged CFCs 
(n = 3 patient samples). One experiment is represented in d, mean ± s.e.m. (P values: two-tailed 
Student’s t-test; *P < 0.05, **P < 0.01, ***P < 0.001). 
Figure 4 p53 and c-MYC abrogation in normal and primitive CML cells. a, CFSE/CD34-
labelled CML cells. Combo, combination. b, Recovery of CFSE
max
 CML cells after 5 days 
treatment (n = 3 patient samples). c, Bone marrow (BM) analyses of human CML, replicated 
twice (2 patient samples), with a minimum of n = 6 mice per arm. d, Bone marrow analyses of 
human cord blood replicated once, n = 5 mice per arm; mean ± s.e.m. (P values: two-tailed 
Student’s t-test; *P < 0.05, **P < 0.01, ***P < 0.001). 
Figure 5 Mechanism and clinical relevance of treatment. a, Molecular synergy for 100 nM 
RITA, 1 µM CPI-203 and RITA plus CPI-203 (Combo) 24 h treatment (NDC=no drug control; 
n=3 patient samples per arm); mean () expression of ‘all’ and ‘extreme’ synergistic genes 
  
summarized as indicated. FC, fold change. b, Enrichment of p53 (far left), apoptosis (second 
left), c-MYC (second right) and differentiation (far right) Molecular Signatures Database 
(MSigDB) signatures. Asterisks indicate significant enrichment specific to combination 
treatment. c, Gene membership of three functional signatures. d, Comparison of transcriptional 
profiles of TKI-R, TKI-NR and baseline CML versus normal (left), and aggressive, indolent and 
baseline CML versus normal (right) for our candidate network (Fig. 1a).  FDRs calculated by 
10,000 permutations. 
Figure 6 Targeting p53 and c-MYC in CML elicits synergistic kill in BCR–ABL1+ LSCs. a, 
White blood cell (WBC) counts and spleen weights normalized to control (dotted line) 
(experiments replicated twice, minimum n = 7 mice per arm; vehicle, no drug control). Combo, 
combination treatment. b–d, Bone marrow stained for CD45.1/2 and further gated on Lin−Sca-
1
+
c-Kit
+
 (LSK). Drug treatments (experiments replicated twice, minimum n = 5 mice per arm). e, 
f, NSG mice in vivo treatment: bone marrow stained for human Ph
+
CD45
+
 (left) and further 
gated on CD34
+
 cells (right). g, Representative CD34
+
 dotplots (experiments replicated twice (2 
patient samples), minimum n = 9 mice per arm); mean ± s.e.m. (P values: two-tailed Student’s t-
test; *P < 0.05, **P < 0.01, ***P < 0.001). 
METHODS 
Patient samples 
Patient samples (PS) were leukapheresis products taken at time of diagnosis with chronic-phase 
CML, with written informed consent in accordance with the Declaration of Helsinki and 
approval of the Greater Glasgow and Clyde National Health Service Trust Institutional Review 
Board. CD34
+
 cells were enriched using CliniMACS (Miltenyi Biotec), with stem cell subsets 
purified by FACS. CML CD34
+
 samples were cultured in serum-free medium (SFM) 
supplemented with growth factors as described previously
16
. Normal CD34
+
 cells were CD34-
enriched leukapheresis products or cord blood maintained as described for CML CD34
+
 samples. 
All PS and relevant clinical data are summarized in Supplementary Table 4. All in vitro work 
was performed with a minimum of 3 PS (3 biological replicates) unless otherwise indicated. 
Unless otherwise indicated each PS was analysed as an individual sample replicated once in an 
experiment. 
  
Cell lines 
The HeLa cell line was obtained from the German Collection of Microorganisms and Cell 
Cultures (DSMZ; originally deposited by ATCC). HeLa cells were subcultured in RPMI 1640 
(10% FCS plus 2 mM L-glutamine, 100 units ml
−1
 penicillin and 100 μg ml−1 streptomycin 
(Gibco- Life Technologies)) (passage 3). The K562 cell line (DSMZ) was subcultured in IMDM 
(10% FCS plus 2 mM L-glutamine, 100 units ml
−1
 penicillin and 100 µg ml
−1
 streptomycin 
(passage <6)); the cell lines were not authenticated between passage 2–6. Cell lines were 
mycoplasma negative in DAPI, microbiological culture, RNA hybridization and PCR assays. 
CML cytoplasmic preparations for MS 
CML and normal CD34
+
 cells were thawed and cultured overnight as described
24
. Cytoplasmic 
preparations were prepared using the Active Motif Nuclear Extraction Kit (Active Motif). 
Materials 
RITA (CAS 213261-59-7; catalogue no. 10006426), Nutlin-3a (CAS 675576-98-4; catalogue no. 
18585) (Cayman Chemical) and Nil (CAS 641571-10-0) (Selleck Chemicals) were stored as per 
manufacturer’s instructions. CPI-203 and CPI-0610 were obtained from Constellation 
Pharmaceuticals and kept as a solid powder at room temperature. Das (Selleck Chemicals) was 
kept as a stock solution (10 mg ml
−1
) in dimethylsulfoxide (DMSO; Sigma-Aldrich) and 
prepared and stored in aliquots at −20 °C. Imatinib mesylate (LC Laboratories) was stored at 
100 mM in distilled water at 4 °C. RG7112 and RG7388 were supplied by Roche. A list of all 
antibodies used is provided in Supplementary Table 8. 
Proteomics 
Methods used have been described
12
. Twenty micrograms of protein was isobarically tagged 
(iTRAQ reagent, ABSciex). Peptides were identified by Reverse phase liquid chromatography 
tandem mass spectrometry (RP-LC-MS/MS) on three different instruments: ABSciex Q-STAR 
Elite, Thermo LTQ Orbitrap Velos, ABSciex TripleTOF 5600. For the 5600 and Elite, dried 
peptide fractions were resuspended in 15 µl 3% (v/v) acetonitrile, 0.1% (v/v) formic acid and 
20 mM citric acid. For each analysis, a 5 µl peptide sample was loaded onto a nanoACQUITY 
UPLC Symmetry C18 Trap (5 µm, 180 µm × 20 mm) and separation of the peptides was 
performed using nanoACQUITY UPLC BEH C18 Column (1.7 µm, 75 µm × 250 mm). For the 
Orbitrap, 10% of the peptide sample was loaded onto Acclaim PepMap µ-Precolumns, analytical 
  
separation of the peptides was performed using Acclaim PepMap RSLC C18 Columns. Data 
were acquired using the information-dependent acquisition (IDA) protocol. 
Elite and 5600 data were processed by a ‘thorough’ search against the 
UniProtKB/SwissProt human database containing 532,146 sequence entries using ProteinPilot 
Software 4.1, revision number 460, Paragon Algorithm 4.0.0.0. Orbitrap data were analysed 
using Proteome Discoverer 1.3. The data were searched using the MASCOT node of Proteome 
Discoverer with the UniProtKB database (release 2011_11). The proteins observed in the three 
data sets demonstrated that using multiple instruments enhanced coverage (Extended Data Fig. 
1). 
Analysis and integration of MS proteomic data 
MS data sets were filtered for peptides observed in all channels (one normal sample was 
removed from all experiments due to poor labelling). Deregulated proteins were identified using 
a threshold of mean ± 2 s.d. on CML versus normal log2 ratios. This candidate list was refined to 
include only those proteins corroborated by (1) log ratio changes of ±0.5 in murine 
Ba/F3 ± BCR–ABL1 MS data12, (2) a complementary CD34+ cell proteomics data set39, and/or 
(3) all instruments within the current experimental data set. A parallel, manual inspection 
retained candidates if (1) log ratios were ≈ ±1.3, or (2) log ratios were lower and neither 
alternative instrument reported differential expression in the opposite direction; this manual 
selection step was blinded. Together, these filtering steps reduced the candidate list to 58 
proteins (see Supplementary Table 1). 
Formation of candidate network 
The MetaCore implementation (13 June 2012) of Dijkstra’s shortest path algorithm7, a general 
purpose algorithm that identifies the shortest paths between ‘seed’ nodes of interest in a graph, 
was used to build a network around the 58 deregulated proteins (the graph used was the fully 
manually annotated MetaCore KB). Paths between seeds were limited to length = 2 and all 
shortest paths of the minimum length were retained in the resulting network. Topology statistics 
(Supplementary Table 2) were calculated using the igraph package in R. 
Transcriptomic data analysis 
Three bulk CD34
+
 (1–3) and four primitive LSC (4–7) CML chronic phase versus normal data 
sets are discussed: (1) E-MTAB-2581: Affymetrix Human Gene 1.0 ST Array transcriptional 
  
data from newly diagnosed CML chronic phase and normal progenitor cells (CD34
+
CD38
+
) from 
G-CSF-mobilized peripheral blood. mRNA was extracted using the RNeasy Mini Kit (Qiagen) 
and DNase I treated on columns using the RNase (RNase)-Free DNase Set (Qiagen). Affymetrix 
GeneChIP analysis was performed using 50 ng of RNA to the manufacturer’s instructions; (2) 
Gene Expression Omnibus (GEO) accession GSE47927 (ref. 40); (3) GEO accession GSE5550 
(ref. 41); (4) ArrayExpress accession E-MTAB-2581 (as described in (1) but for CD34
+
CD38
−
 
cells); (5) GEO accession GSE47927 (ref. 40); (6) GEO accession GSE24739 (ref. 42); and (7) 
ArrayExpress accession E-MTAB-2508 (ref. 43). 
CEL files were obtained directly from collaborators or public repositories. All 
transcriptional data were RMA normalized with the exception of GSE5550 for which only the 
VSN
44
 normalized data were available. Log2 scale expression values were analysed using 
limma
45
 (P value correction by Benjamini–Hochberg46). In calculating the correlations and MI 
statistics (Fig. 1b, c and Extended Data Fig. 1), multiple probesets corresponding to single genes 
were median averaged. 
Calculating correlations across multiple data sets 
Ensembl’s web services were used to map between (1) human and murine data sets via 
orthologues and (2) human transcriptomic and proteomic data sets via HUGO Gene 
Nomenclature Committee (HGNC) symbols. The Bioconductor package biomaRt (v.2.18.0) was 
used in R (v.3.0.1). Pearson’s product moment correlation coefficients (r) were calculated across 
data sets for the 58 candidates and the 30 networked candidates (rc and rn respectively in 
Extended Data Fig. 1). Resulting r
2
 values quantify the proportion of variability captured by the 
linear relationship and r
2
 is defined as r
2
n/r
2
c, that is, the ratio of r
2
 for the 30 networked 
candidates to the r
2
 for the 58 candidates. FDRs for the r
2
 observed were generated by 
considering 10,000 random samplings of each data set and counting the number of random 
samples meeting or exceeding the r
2
 and r
2
n statistics. 
Calculation of MI 
We calculated the MI values for 10,000 random subsets (of size 30) to generate a distribution of 
MI values that we would expect by chance (expression values binned between −3 and 3, bin 
width = 0.1; entropy package in R); these are the values summarized by the distributions plots in 
  
Fig. 1c and Extended Data Fig. 1. The FDR values represent the proportion of random subsets 
that generate an MI greater than or equal to the MI for the network. 
Calculation of proteomic/primitive transcriptional consistency FDR 
Of the 30 proteins in Extended Data Fig. 1, 21 showed consistency of deregulation in at least 
three of the primitive transcriptional data sets and the bulk proteomic data set. To assess how 
likely it would be to observe such consistency by chance, the data were randomly permuted 
10,000 times and permutations exhibiting similar deregulation consistency (that is, deregulation 
correspondence across four data sets) were recorded. 
Topological analysis of p53/c-MYC in other MS data sets 
Comparison of leukaemogenic PTK proteomic effects and three primary proteomics data sets, 
describing two types of breast cancer
11
 (3 ductal carcinoma in situ and 4 invasive carcinoma 
breast cancer patient samples with matched normal samples), three types of prostate cancer
10
 (24 
non-aggressive, 16 aggressive, 25 metastatic prostate cancer patient samples and 10 normal 
samples) and cervical
9
 cancer, were obtained directly from the authors. In each data set, 
deregulated proteins were identified using z-scores ± 2 when considering cancer versus normal 
log2 ratios and subjected to the same MetaCore network building process as described earlier. In 
the case of the cervical cancer data set no network could be found and the data were removed 
from the analysis. In addition, 50 sets of 58 random proteins were generated from the list of all 
proteins observed across the three MS data sets and subjected to the same network building 
process. The ratio dout/din was calculated to quantify the bias of outgoing to incoming 
connections to/from p53 and c-MYC (Fig. 1d). 
TKI-R/TKI-NR and aggressive/indolent CML transcription  
The PB ‘validation’ set TKI-R/TKI-NR samples in GEO data set GSE14671 were integrated 
with a material-matched CML versus normal data set (CD34
+
CD38
+
 cell data from ArrayExpress  
E-MTAB-2581) using COMBAT
47
 (Bioconductor package inSilicoDb v.1.10.1). All probeset-to-
probeset mappings between the Affymetrix HG U133+2 and Affymetrix HuGe 1.0 ST chips 
(obtained via Bioconductor’s biomaRt package) were retained and used by COMBAT. The TKI-
R and TKI-NR samples were compared to the integrated normal data (using limma) to generate 
logFC values representing differential expression (see left two lanes in each panel of Fig. 5e). 
The pattern of differential expression in the TKI-R/TKI-NR versus normal comparisons was then 
  
compared to that of CML versus normal, as calculated separately by limma in the material-
matched data sets (E-MTAB-2581) (see right lane in each panel of Fig. 5e) to provide a baseline 
CML versus normal comparison. Transcriptional profiles for probe pairs corresponding to the 30 
members of the candidate network were identified using HGNC symbols (data corresponding to 
TARDBP were removed due to the large number (66) of corresponding probe pairs). An FDR 
was calculated using 10,000 re-samplings of the merged data set to describe the likelihood of 
observing a correlation as high or greater by chance. The transcriptional data for the aggressive 
and indolent samples in ArrayExpress data set E-MIMR-17 were processed as described earlier, 
but integrated with the CML and normal CD34
+
 data set GSE5550 using all probeset-to-probeset 
mappings between the Affymetrix U133a and Affymetrix HG Focus chips (again obtained using 
biomaRt). 
Enrichment of MSigDB signatures 
For the candidate network analysis (the results of which are shown in Supplementary Table 3), 
MSigDB signatures (C2: curated genesets) were accessed via the c2BroadSets object in 
GSVAdata v.1.0.0 using R. Enrichment scores were calculated using the hypergeometric 
distribution as implemented by dhyper(). Signatures corresponding to CML, c-MYC and p53 
related biology were extracted using appropriate regular expressions on the signature name. In 
the RNA-seq analysis (Fig. 5b), the MSigDB signatures (C2: curated genesets) were identified as 
significantly differentially expressed in the TMM/VOOM-normalized RNA-seq data using 
GSVA
48
 and limma
49
. Significant pathways were identified using an FDR = 0.05 threshold on 
corrected P values
46
. The p53, apoptosis, c-MYC and differentiation signatures were extracted 
using appropriate regular expressions on the signature name. 
Enrichment of PANTHER pathways 
The top 1,500 differentially expressed genes (as ranked by increasing P value, calculated by 
limma
49
) were identified comparing treated/untreated samples. These genes and their logFCs for 
each arm were uploaded to PANTHER (http://www.pantherdb.org/) and subjected to a Mann–
Whitney U-test
50
 to identify enrichment of PANTHER pathways. Extended Data Figure 6b 
shows enrichment results (without Bonferroni correction) including the hypothesized direction of 
pathway deregulation. 
  
Cell counting and apoptosis assays 
CML CD34
+
 cells were seeded at 1–2 × 106 cells ml−1 before drug treatment and counted by 
trypan blue (Sigma-Aldrich) exclusion. Apoptosis was quantified by staining with annexin-V–
APC and DAPI. In specified experiments, CML and human cord CD34
+
 cells were labelled with 
CD34–APC and CD38–FITC or PerCP–Cy5.5 and sorted using the FACSAria (BD). The 
selected CD34
+
CD38
−
 cells were analysed 72 h after drug treatments. To measure the dose–
effect relationship of each drug and its combination and to determine synergy, CIs were 
calculated using the Calcusyn software package (BioSoft). Except where documented, all results 
are expressed as a mean ± s.e.m. 
CFC assay 
CD34
+
 cells were treated for 72 h at the indicated concentrations of RITA, CPI-203 and Das. 
Drug-treated cells (2,000 cells per plate) were washed and seeded in Methocult H4435 
(STEMCELL Technologies). CML cells were transduced with lentivector constructs and sorted 
then washed and seeded into methylcellulose. Colonies were assessed 10–14 days after plating. 
Western blotting 
CD34
+
 cells were lysed in RIPA buffer with inhibitors and western blots were performed as per 
standard protocols. 
Immunofluorescence microscopy 
CML CD34
+
 cells were left untreated or treated with the indicated drugs for 24 h. Cells were 
harvested and spotted onto slides coated with poly-L-lysine and fixed with 3.7% (w/v) 
formaldehyde and permeabilized using a 0.25% (w/v) Triton-PBS solution for 15 min. Cells 
were blocked with 5% (w/v) BSA-PBS and stained with primary and secondary antibodies. Cells 
were concurrently stained with DAPI. Cells were imaged using a Zeiss Imager M1 AX10 
fluorescence microscope (Carl Zeiss) and subjected to deconvolution (AxioVision software; Carl 
Zeiss) for image manipulation. Fluorescent signal was measured in three dimensions by Image 
Processing and Analysis in Java (Image J) program. 
Tracking cell divisions 
CFSE (Molecular Probes) and CD34 staining were performed and cell divisions were identified 
as described previously
3
. 
  
Lentivirus transduction 
The pCMV-VSV-G and pCMV-HIV1 were provided by J. Rossi. The pLKO-GFP came from K. 
Kranc. The following optimized pLKO vectors were purchased from Open Biosystems and 
subcloned into the pLKO-GFP vector: (1) TRCN0000003380: MDM2 shRNA bacterial stock 
NM_002392.x-1495s1c1 (ref. 51); (2) TRCN0000355728: MDM2 shRNA bacterial stock 
NM_002392.3-1496s21c1; (3) TRCN0000174055: c-MYC shRNA bacterial stock 
NM_002467.2-1377s1c2 (ref. 52); (4) TRCN0000039642: c-MYC shRNA bacterial stock 
NM_002467.2-1377s1c1 (ref. 53). 
Transduction of HeLa cell lines was performed at a MOI 1-10 with 70–95% of the cells 
expressing GFP after 48 h. For transduction, CD34
+
 cells were cultured in medium supplemented 
with growth factors (IL-3 25 ng ml
−1
, IL-6 10 ng ml
−1
, Flt-3L 100 ng ml
−1
, SCF 50 ng ml
−1
, TPO 
100 ng ml
−1
) for 48 h, followed by two exposures to concentrated virus-containing supernatants 
(Multiplication of infection= 5) via spinoculation. Cells were harvested 48 h after second 
transduction and analysed or sorted for GFP positivity. 
Transduced viable cells (assessed as annexin-V
−
/DAPI
−
 percentages multiplied by the 
absolute cell count) are presented as a percentage of CML CD34
+
 cells transduced with scramble 
control. 
Immunodeficient mouse engraftment 
For the ex vivo drug studies CML (2 × 10
6
 cells per mouse) or cord blood (2 × 10
5
) CD34
+
 cells 
were cultured with the indicated drugs (RITA 70 nM, CPI-203 1 µM and Das 150 nM). After 
48 h cells were transplanted via tail vein into female 8–10-week-old sublethally irradiated 
(2.5 Gy) NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ NSG mice (The Jackson Laboratory). Human cells 
were assessed by anti-human CD45 antibody analysed by flow cytometry. Specific cell subsets 
were detected using antibodies to human CD34, CD33, CD11b, CD14 and CD19 (mouse 
antibody table in Supplementary  Table 8).  
For the in vivo drug treated NSG experiments, CML (2 × 10
6
 cells per mouse) CD34
+
 
cells were transplanted via tail vein into female 8–10-week-old sublethally irradiated (2.5 Gy) 
NSG mice (The Jackson Laboratory). After 4 weeks, mice were treated with RG7388 (75–
100 mg kg
−1
, oral gavage once daily), CPI-203 (6–7.5 mg kg−1, intraperitoneally twice daily) or 
Nil (50 mg kg
−1
, oral gavage once daily) for 3–4 weeks. Two CML samples were assessed 
  
separately, each performed with 4–5 mice per drug arm per experiment. Results presented 
represent data from both experiments (each experiment normalized to vehicle). To quantify the 
frequency of BCR–ABL1+ cells within the engrafted human CD45+ cells, dual-fusion D-FISH 
was performed as previously described
3
. 
Transgenic mouse model 
Inducible (tetracycline (TET)-based) DTG (SCLtTAxBCR-ABL) donor mice in a C57BL/6 
(CD45.2) background were a gift from D. G. Tenen. B6.SJL-Ptprc
a
 Pepc
b
/BoyJ (CD45.1) 
recipients (a mixture of female and males between 8–10 weeks old) were purchased from 
Charles River Laboratories. 
Bone marrow transplantation and analysis of disease 
Bone marrow cells of DTG mice (1 × 10
6
) were injected into the tail veins of 10-week-old 
irradiated (2 doses of 4.25 Gy, 3 h apart) recipients. TET was continued for 2 weeks after 
radiation. Tail veins bleeds were performed weekly after TET removal and Gr1/Mac1 
percentages (flow cytometry), white blood cells, neutrophils and haemoglobin (Hemovet) were 
monitored. 
DTG in vivo drug treatment 
Drugs were administered to DTG mice 5 weeks after transplantation, over a 4-week period. Nil 
75 mg kg
−1
 once daily, CPI-0610 15 mg kg
−1
 twice daily and RG7112 50 mg kg
−1
 once daily, all 
by oral gavage. For no drug control mice were administered the vehicles at the same 
concentrations and volumes as used for the combination arm. 
Flow analysis 
Peripheral blood, bone marrow and spleen cells were stained using appropriate antibodies and 
analysed using a FACSCanto or FACSAria machine (BD Biosciences). 
Husbandry 
All experiments were performed in accordance with the local ethical review panel, the UK Home 
Office Animals Scientific Procedures Act, 1986, and UK Co-ordinating Committee on Cancer 
Research (UKCCCR) and National Cancer Research Institute (NCRI) guidelines. 
  
Animals were kept in regulated facilities, monitored daily, and all experiments were 
carried out in compliance with UK Home Office guidelines. Mice were genotyped by 
Transnetyx. 
RNA-sequencing 
Sample preparation. CML CD34
+
 cells were seeded in 48-well plates at 1–2 × 106 cells ml−1, 
before drug treatment (RITA 50 nM, CPI-203 1 µM, Nil 5 µM) for 24 h. After treatment, RNA 
was extracted using RNeasy Plus Mini Kit (Qiagen). 
Library generation. RNA-seq libraries were generated using TruSeq Stranded Total RNA (part 
no. 15031048 Rev. E October 2013) kits. Ribosomal depletion was performed on 1 μg of RNA 
using Ribo-Zero Gold before a heat fragmentation step aimed at producing libraries with an 
insert size between 120–200 bp. Complementary DNA was synthesized from the enriched and 
fragmented RNA using SuperScript II Reverse Transcriptase (Invitrogen) and random primers. 
The cDNA was converted into double-stranded DNA in the presence of dUTP to prevent 
subsequent amplification of the second strand. After 3′ adenylation and adaptor ligation, libraries 
were subjected to 15 cycles of PCR to produce RNA-seq libraries. Before sequencing, RNA-seq 
libraries were qualified and quantified via Caliper’s LabChip GX (part no. 122000) instrument 
using the DNA High Sensitivity Reagent kit (product no. CLS760672). Quantification of 
libraries for clustering was performed using the KAPA Library Quantification Kits for Illumina 
sequencing platforms (kit code KK4824) in combination with Life Technologies QuantStudio 7 
real-time PCR instrument. Libraries were finally pooled in equimolar ratios and sequenced on 
Illumina’s NextSeq500 platform using 75 bp paired-end high-output runs.  
Alignment and analysis. Sequencing reads were aligned to the genome (GRCh38/release 80 
primary assembly as obtained via ftp.ensembl.org) using Subread (v.1.4.6-p3)
54
. RNA-SeQC was 
used to confirm adequate mapping quality and gene-level counts were calculated using Subread’s 
featureCounts algorithm
55
. Count data for each arm were normalized independently by TMM
56
 
(as implemented in the Bioconductor package edgeR) and VOOM
57
 (as implemented in the 
Bioconductor package limma). Genes with <3 cpm in three samples were removed from further 
analysis. Differential expression was identified using limma
49
 (using Benjamini–Hochberg46 
correction). 
  
Definition of synergy 
Genes were described as loosely synergistic if (1) RITA, CPI-203 and combined treatment all 
induced deregulation in the same direction, (2) the deregulation in response to the combined 
treatment was significant (q < 0.05), and (3) the deregulation induced by the combined treatment 
was greater than both RITA and CPI-203 in isolation. A more extreme definition had an 
additional criteria of the log ratio of the observed and additive effect being >0.6 (corresponding 
to a 150% increase). 
Statistical analysis 
For in vitro experiments a minimum of 3 patient samples were chosen as a sample size to ensure 
adequate power. For all animal studies, each experiment was replicated twice in the laboratory 
with a minimum number of 5 mice per arm, unless indicated. NSG mice were excluded from 
analyses if they died of radiation poisoning (within 10 days of being irradiated, out of a 16-week 
procedure). For DTG mice, mice were excluded from analysis if leukaemic cells (CD45.2) failed 
to engraft host mice (CD45.1
+
) and therefore would not develop leukaemia. This was determined 
1 week before drug treatment. Patient samples were only excluded if clinical data identified 
patient sample as entering blast crisis. Pre-established criteria also included that if a sample data 
point deviated 2 standard deviations from the mean, it was to be excluded, but this was not 
applied to the data in main or extended data. Group allocation to mice was done as mice were 
either purchased and subsequently numbered or weaned, to remove any investigator bias. For 
both NSG and DTG mice studies, all mice were randomly assigned treatment groups, ensuring 
all animals were of equal health and leukaemic status, within normal variability. Mice were 
assessed at predetermined time points: NSG mice were assessed at 8 and 16 weeks and DTG 
mice were assessed 4 weeks after drug treatment, so there was minimized bias as to assessing 
outcome. All mice were cared for equally in an unbiased fashion by animal technicians and 
investigator. No blinding was done. 
Unless indicated, data are presented as the mean ± s.e.m. and P values were calculated by 
two-tailed Student’s t-test using GraphPad Prism software. Significant statistical differences 
(*P < 0.05, **P < 0.01, ***P < 0.001) are indicated. 
Code availability 
All computer code was implemented in R and is available from the authors upon request. 
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Extended Data Figure 1 | BCR–ABL1 drives a proteomic signature mediated by p53 and c-
MYC. a, b, Equivalent to Fig. 1b, c with additional information regarding the correlations 
calculated from the complete list of 58 candidate proteins (rc) in addition to the correlations for 
the candidate network (rn) and the background (r0). Also shown is the gain in r
2
 obtained for the 
candidate network as compared to the r
2
 obtained for the candidate list as a whole (r
2
). FDR 
calculated from 10,000 re-samplings. c, Expression changes of the network components (shown 
as bar plots) in the context of quiescent and primitive CML cells; data shown in each panel (left 
to right) are (1) CD34
+
 protein log2 ratios (n=3 patient samples, n=2 normal samples); (2) 
CD34
+
Hst
lo
Py
lo
 transcript logFC (ArrayExpress accession E-MTAB-2508); (3) CD34
+
Hst
lo
Py
lo
 
transcript logFC (GEO accession GSE24739); (4) CD34
+
CD38
−
 logFC (ArrayExpress accession 
E-MTAB-2581); and (5) Lin
−
CD34
+
CD38
−
CD90
+
 logFC (GEO accession GSE47927). Down-
/upregulation is indicated by turquoise/red, respectively. Where multiple probesets were found 
for individual genes, the probeset corresponding to the maximal log ratio was selected. d, e, 
  
Correlation of the candidate network in progenitor (CD34
+
) CML cells: CD34
+
CD38
+
 progenitor 
(top); common myeloid progenitor Lin
−
CD34
+
CD38
+
CD123
+
CD45RA
−
 (middle); and CD34
+
 
cells (bottom). As in a, b, correlations for the background (r0), candidate list (58 proteins, rc) and 
candidate network (Fig. 1a, rn) are shown. Also shown is the gain in r
2
 obtained for the candidate 
network as compared to the r
2
 obtained for the candidate list as a whole (r
2
). FDR calculated 
from 10,000 re-samplings; MI statistics corresponding to FDRs<0.05 are coloured red, 
FDRs<0.10 are coloured grey. f, A Venn diagram showing the overlap in protein identification 
of the three MS instruments: ABSciex Q-STAR Elite (Elite), Thermo LTQ Orbitrap Velos (Orbi) 
and ABSciex TripleTOF 5600 (5600). 
Extended Data Figure 2 | Validation of network candidates. a, HDM2 and c-MYC 
knockdown using shRNA constructs. Western blots of c-MYC, HDM2, p53 and Hsp90 in HeLa 
cells transduced with lentiviral constructs specific for either c-MYC (2 constructs), HDM2 (2 
constructs) or scrambled control (1 construct). KD, knockdown. b–d, CML CD34+ cells were 
transduced with either lentiviral (GFP) shRNA constructs to HDM2 (constructs 1, 2), c-MYC 
(constructs 1, 2) or scramble control (1 construct). b, Transduced viable GFP
+
 cells (assessed as 
annexin-V
−
/DAPI
−
/GFP
+
 percentages multiplied by the absolute cell count) are presented as a 
percentage of CML CD34
+
 cells transduced with scramble control (n = 3 patient samples). c, 
Early apoptosis levels (assessed as annexin-V
+
/DAPI
−
/GFP
+
) after transduction of CML CD34
+
 
cells (n = 3 patient samples) as described in b. Statistical significance was calculated by a two-
tailed Student’s t-test and error bars represent the s.e.m. 
Extended Data Figure 3 | RITA and CPI-203 synergize to eliminate CML CD34
+
 cells. a, b, 
Western blots of CML CD34
+
 cells untreated or treated with 50 nM RITA; 1 µM CPI-203; or the 
combination of 50 nM RITA and 1 µM CPI-203 or 150 nM Das for 8 h (a) and 48 h (b). c, p53 
(red, nucleus in blue) 24 h after treatment in CML CD34
+
 cells. d, RITA, CPI-203 and 
combination drug treatment eliminates CD34
+
 CML cells through mechanisms probably 
dependent on apoptosis; after 72 h of drug treatment apoptosis levels were assessed (annexin 
V/DAPI) using flow cytometry techniques. e, RITA or Nut cannot induce death of K562 cells 
that lack p53. K562 cells were treated with either 50 µM RITA or 10 µM Nut and after 72 h of 
drug treatment, apoptosis levels were assessed (annexin V/DAPI) using flow cytometry 
techniques. 
  
Extended Data Figure 4 | RITA and CPI-203 synergize to eliminate CML cells a, CD34
+
 
CML cells were treated with Nut and CPI-203 for 72 h with apoptosis levels assessed (annexin 
V/DAPI) using flow cytometry techniques. b, Treatment of CD34
+
 CML cells with Nut results in 
the elimination of early and late progenitor cells as assessed by the functional colony-forming 
capacity of drug-treated CML cells. c, Sequential drug treatments (n = 3 patient samples; drug 
one for 24 h, then both for 48 h). d, Sequential knockdown treatments (n = 3 patient samples; 
knockdown one for 24 h, then both for 48 h), mean ± s.e.m. (P values: two-tailed Student’s t-test; 
*P < 0.05, **P < 0.01, ***P < 0.001). e, CML CD34
+
 primary samples were pre-treated or not 
with imatinib mesylate (1 µM) for 8 h followed by RITA (50 nM), CPI-203 (1 µM) or the 
combined treatment (RITA plus CPI-203) for 72 h (right three columns). Cell counts were 
obtained using trypan blue exclusion. 
Extended Data Figure 5 | RITA and CPI-203 selectively eliminate LSCs. a, b, Viable cell 
counts (n = 3 patient samples) (a); apoptosis in normal CD34
+
 cells (n = 3 patient samples) in 
response to RITA and/or CPI-203 (b). c, Gated CML CD34
+
CD38
−
 cells 72 h after treatment 
(n = 4 patient samples). d, Ex vivo protocol for CML/cord blood CD34
+
 cells in NSG mice (n = 5 
mice per arm). e, f, Targeting p53 and c-MYC in CML eliminates NSG repopulating leukaemic 
stem cells. CML CD34
+
 cells were treated with RITA (70 nM) and/or CPI-203 (1 µM) or Das 
(150 nM) for 48 h and recovered cells were injected intravenously into 8–12-week-old, 
sublethally irradiated (2.5 Gy) NSG mice (2–4 mice per arm). e, Percentage of human CD45+ 
cell levels in peripheral blood (PB) at 8, 12 and 16 weeks. f, Percentages of human CD45
+
, 
CD34
+
, CD33
+
, CD11b
+
, CD19
+
 and CD14
+ 
cells in the bone marrow at 16 weeks. g, CML bone 
marrow analyses of CD33, CD11b, CD19 and CD14 from a CML sample determined to engraft 
both BCR–ABL-positive and -negative cells. h, D-FISH analyses of bone marrow human 
engraftment studies shown in g performed twice (2 patient samples) with a minimum of n = 6 
mice per arm; mean ± s.e.m. (P values: two-tailed Student’s t-test; *P < 0.05, **P < 0.01, 
***P < 0.001). 
Extended Data Figure 6 | Mechanism of LSC elimination and clinical scope. a, Enrichment 
of p53 (top); apoptosis (second from top); c-MYC (second from bottom); and differentiation 
MSigDB signatures (bottom) in the four treatment arms (n=3 CML patient samples per arm) 
(columns named as per b). Equivalent to Fig. 5b, but with named MSigDB signatures. b, 
Enrichment of PANTHER pathways in the four treatment arms. Pathway enrichment calculated 
  
from the top 1,500 genes, as ranked by increasing P value (top); only those genes exhibiting an 
absolute FC of >0.5 in each arm (bottom left); only those genes exhibiting a P value of >0.05 in 
each arm (bottom right). c, Assessing molecular synergy of the combined RITA plus CPI-203 
treatment, as compared to the individual RITA and CPI-203 arms of the RNA-seq experiments in 
the three in silico functional signatures: p53/apoptosis (left); c-MYC (middle); and 
differentiation (right). Mean expression is shown as a solid line. 
Extended Data Figure 7 | Mechanism of LSC elimination and clinical scope continued. a, 
Gene expression patterns (logFC, n=3 patient samples per arm) shown for the members of the 
three broad signatures identified in silico: p53/apoptosis (left); c-MYC (middle); and 
differentiation (right) (*q < 0.05); data are ordered by increasing logFC in response to Combo 
treatment, from downregulation at the top to upregulation at the bottom. Corresponding 
expression data are provided in Supplementary Tables 5–7. b, Differential expression of CD34 
and CD133 (markers of stemness) in the four arms of the RNA-seq experiment. c, Apoptosis 
levels assessed (annexin V
+
/DAPI) using flow cytometry on a TKI-NR CD34
+
 sample after 72 h 
treatment with RITA and CPI-203 as indicated. 
Extended Data Figure 8 | RG7112 and CPI-0610 as a combination decrease BCR–ABL+ 
cells. a, b, DTG mice in vivo treatment (a): neutrophils normalized to control (dotted line) (b). c, 
Bone marrow cells stained for CD45.1/2. Drug treatment arms (minimum of n = 7 mice) 
mean ± s.e.m. (P values: two-tailed Student’s t-test; *P < 0.05, **P < 0.01, ***P < 0.001). 
